Lesa Dawman

Dr. Lesa Dawman


Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 September 2020 in Journal of Tropical Pediatrics
Verified
Journal Article
Open access
PDF file
PPPrateek Kumar Panda
Prateek Kumar Panda
ISIndar Kumar Sharawat
Indar Kumar Sharawat
PPPragnya Panda
Pragnya Panda
VNVivekanand Natarajan
Vivekanand Natarajan
RBRahul Bhakat
Rahul Bhakat
LDLesa Dawman
Lesa Dawman
Background: Knowledge about neurological complications of COVID-19 in children is limited due to the paucity of data in the existing literature. Some systematic reviews are available describing overall clinical features of COVID-19 in children and neurological complications of COVID-19 in adults. But to the best of our knowledge, no systematic review has been performed to determine neurological manifestations of COVID-19.Methods: Six different electronic databases (MEDLINE, EMBASE, Web of Science, CENTRAL, medRxiv and bioRxiv) were searched for articles related to COVID-19 and neurological complications in children. Studies/case series reporting neurological manifestations of COVID-19 in patients aged ≤18 years, as well as case reports, as neurological complications appear to be rare. The pooled estimate of various non-specific and specific neurological manifestations was performed using a random effect meta-analysis.Results: Twenty-one studies/case series and five case reports (3707 patients) fulfilled the eligibility criteria and were included in this systematic review, from a total of 460 records. Headache, myalgia and fatigue were predominant non-specific neurological manifestations, presenting altogether in 16.7% cases. Total of 42 children (1%) were found to have been reported with definite neurological complications, more in those suffering from a severe illness (encephalopathy—25, seizure—12, meningeal signs—17). Rare neurological complications were intracranial hemorrhage, cranial nerve palsy, Guillain–Barré syndrome and vision problems. All children with acute symptomatic seizures survived suggesting a favorable short-term prognosis.Conclusion: Neurological complications are rare in children suffering from COVID-19. Still, these children are at risk of developing seizures and encephalopathy, more in those suffering from severe illness.

2 February 2019 in Archives of Osteoporosis
Verified
Journal Article
Closed access
PDF file
ISIndar Kumar Sharawat
Indar Kumar Sharawat
LDLesa Dawman
Lesa Dawman

19 January 2022 in Archives de Pédiatrie
Verified
Journal Article
Closed access
RSRajni Sharma
Rajni Sharma
BJBikramjit Singh Jafra
Bikramjit Singh Jafra
KTKaralanglin Tiewsoh
Karalanglin Tiewsoh
KKKrishan Kumar
Krishan Kumar
NKNavpreet Kaur
Navpreet Kaur
LDLesa Dawman
Lesa Dawman

1 September 2021 in Journal of Family Medicine and Primary Care
Verified
Journal Article
Open access
PDF file
PPPrateek Kumar Panda
Prateek Kumar Panda
ISIndar Kumar Sharawat
Indar Kumar Sharawat
VNVivekanand Natarajan
Vivekanand Natarajan
RBRahul Bhakat
Rahul Bhakat
PPPragnya Panda
Pragnya Panda
LDLesa Dawman
Lesa Dawman
Background: Exact information about the efficacy of various medications proposed by regulatory bodies in children with COVID-19 is limited due to the lack of controlled trials in the existing literature. Methods: Different electronic databases (MEDLINE, EMBASE, Web of Science, COCHRANE CENTRAL, LitCovid, medRxiv, and bioRxiv) were searched for articles describing the management of COVID-19 cases in children with 18 shortlisted medications. Prospective/retrospective studies/case series (with at least 20 cases) reporting COVID-19 in patients aged ≤14 years were searched to collect information regarding clinical details and severity of participants, medications used, and outcome. The pooled estimate of these parameters across studies was performed using a random-effect or fixed-effect meta-analysis depending on the degree of heterogeneity. Results: From a total of 5794 records, 97 studies/case series (8243 patients) fulfilled the eligibility criteria and were included in this systematic review. A total of 21% children received at least one medication specifically used for COVID-19. While antivirals were used in 15.3% of children, remedesivir was the most commonly used antiviral drug in 6.2% of included children without many reports of serious adverse effects. There was a more prevalent use of anti-inflammatory medications including corticosteroids (27.8%, P = 0.01). Total 91% of severe cases described in literature in children received some anti-inflammatory medications. Among them, corticosteroids (17%) and Intravenous immune globulin (IVIG) (17.5%) were the most predominant followed by interferon (4.2%), tocilizumab (1.5%), and anakinra (0.8%). The most predominant therapy among multisystem inflammatory syndrome in children (MIS-C) cases were IVIG (81%), followed by aspirin (67%), corticosteroids (64%), inotropes (62%), and anticoagulation (56%, mostly low molecular weight heparin, LMWH). Overall mortality was only 1.3%, but when we analyzed separately including only cases with moderate and severe disease, the mortality rate was 4.6%. Conclusion: Among pharmacological modalities, anti-inflammatory agents like corticosteroids and antivirals like remdesivir have the most promising evidence for severe cases of pediatric COVID-19. Intravenous immunoglobulin and other anti-inflammatory/immunomodulatory agents like anakinra, aspirin, and anticoagulants have important therapeutic role in cases with MIS-C. Most of the mild cases recover with conservative treatment only.

6 October 2021 in The American Journal of Tropical Medicine and Hygiene
Verified
Journal Article
Closed access
PDF file
PPPrateek Kumar Panda
Prateek Kumar Panda
PPPragnya Panda
Pragnya Panda
LDLesa Dawman
Lesa Dawman
RSRakesh Kumar Sihag
Rakesh Kumar Sihag
ISIndar Kumar Sharawat
Indar Kumar Sharawat
: Thalidomide, an anti-inflammatory and immunomodulatory agent, has a potential role in cases with central nervous system tuberculosis (CNS-TB) with paradoxical reactions. Although several articles have described the use of thalidomide in CNS-TB, no systematic review has been performed in this regard. Different electronic databases were searched for articles describing the use of thalidomide in patients with CNS-TB. For determining pooled estimates in the quantitative review, studies with a minimum sample size of 5 were only considered, whereas for qualitative synthesis even single case reports were included. Fixed or random effect models were used suitably depending on the degree of heterogeneity. Fourteen articles describing a total of 107 patients (98 children and 9 adults) were selected from 156 records. A favorable clinical response was observed in 89% of patients with CNS-TB who had paradoxical reactions refractory to corticosteroids. Majority of the studies used a dose of 2–6 mg/kg/day and around 24% suffered from at least one adverse effect, with a mortality of 5%. Predominant adverse effects were rash (9.5%), neuropathy (6%), and elevated liver transaminases (9.5%). Only one placebo-controlled trial has been performed till now, which showed that high-dose thalidomide has numerous adverse effects, without any clinically significant improvement as compared with placebo. While in HIV-positive patients with TB-immune reconstitution inflammatory syndrome thalidomide was helpful in around 82% of cases. Low-dose thalidomide is helpful in patients with CNS-TB who had a paradoxical reaction and unresponsive to corticosteroids. Large, randomized trials are needed to provide more concrete information regarding the safety and efficacy of thalidomide.

6 October 2020 in Clinical and Experimental Nephrology
Verified
Journal Article
Closed access
PDF file
AVAarthi Viswanathan
Aarthi Viswanathan
LDLesa Dawman
Lesa Dawman
KTKaralanglin Tiewsoh
Karalanglin Tiewsoh
ASAkshay Kumar Saxena
Akshay Kumar Saxena
SDSourabh Dutta
Sourabh Dutta
DSDeepti Suri
Deepti Suri